InterMune could raise $200M in stock, notes deal

InterMune Inc. plans to raise $100 million through convertible notes and sell 4 million shares of common stock that could add another $100 million, the company said Monday.
The timing demonstrates some confidence by the Brisbane-based biotech drug developer (NASDAQ: ITMN) that its lung disease drug, Esbriet, can hit blockbuster status.